4.2 Article

Novel approaches to bone comorbidity in Cushing's disease: an update

期刊

PITUITARY
卷 25, 期 5, 页码 754-759

出版社

SPRINGER
DOI: 10.1007/s11102-022-01252-w

关键词

Cushing's disease; Osteoporosis; Vertebral fractures; Bone mineral density; Vertebral morphometry; Glucocorticoids

资金

  1. Pfizer
  2. Takeda Pharmaceutical Co.

向作者/读者索取更多资源

Skeletal complications, including reduced bone mineral density and vertebral fractures, are common in patients with Cushing's disease. A new approach combining various tools is needed to improve diagnosis and management of these bone comorbidities in all CD patients.
Skeletal complications are frequent and clinically relevant findings in Cushing's disease (CD) since an uncoupled suppressed bone formation and enhanced bone resorption leads to a marked skeletal damage with a rapid increase of fracture risk. Reduced Bone Mineral Density (BMD) has been consistently reported and osteopenia or osteoporosis are typical findings in patients with CD. Vertebral Fractures (VFs) are frequently reported and may occur even in patients with an only mild reduction of BMD, representing nowadays a still under- or misdiagnosed comorbidity of these patients being frequently asymptomatic. A novel approach combining different available tools such as BMD evaluation and vertebral morphometry, in order to improve diagnosis, management, and follow-up of bone comorbidity in all patients affected by CD, is needed. This approach is foreseen to be a crucial part of management of patients with CD, particularly in Pituitary Tumor Center of Excellence since VFs, the landmark of the bone involvement, may occur early in the history of the disease and may represent a relevant risk factor for further fractures, reduced quality of life and survival and need for pharmacologic prevention and treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据